Want to join the conversation?
$DVA 2Q15 Q&A: Margaret of William Blair: As we think about the non-acquired dialysis patient growth as we go out over the next several quarters, is that 3.7% treatment growth similar to that patient growth? Kent, CEO: We hope we can do better than how we did this quarter, but right now we can't guarantee that.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.